Physician profile
David Liskov
NPI 1780683417
$2,366.08
in general payments reported to CMS, 2019-2025
17 companies · $960 in 2025
The $960 reported for 2025 was more than what 83% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $114 · 2021: $30.74 · 2022: $84.38 · 2023: $443 · 2024: $559 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.51 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $470.94 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $469.10 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $263.18 | 2020-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $234.34 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $221.37 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $197.32 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $133.29 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $72.12 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.56 | 2025 | Caplyta |
| Lundbeck LLC | $41.88 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $40.18 | 2023-2025 | Auvelity |
| Corium, LLC | $32.36 | 2023 | Azstarys |
| Indivior INC. | $29.28 | 2023-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $28.20 | 2023 | Trintellix |
| Eisai INC. | $24.73 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $21.09 | 2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $18.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liskov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.